Oregon Department of Fish and Wildlife rejects fish passage waiver, putting project on hold
A fish passage waiver was all that stood in the way of the city of Prineville and Ochoco Irrigation District moving forward on a hydroelectric power project on Bowman Dam.
That waiver was denied by Oregon Department of Fish and Wildlife last fall, so the two local entities officially pulled the plug earlier this month, terminating its Federal Energy Regulatory Commission preliminary permit. It s unfortunate, said City Engineer Eric Klann.
Since passage of the Crooked River Collaborative Water Security and Jobs Act paved the way for hydropower generation on Bowman Dam, city and OID officials had been trying to get approval to build a 3-megawatt plant on the dam. The project cleared most hurdles but still needed to account for the affect the dam will have on fish passage along the river.
Scientists Find Promising Avenue to Restore Cognitive Function Impaired by Alzheimer s Disease nyu.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nyu.edu Daily Mail and Mail on Sunday newspapers.
Alzheimer s Disease
Alzheimer s was discovered more than 100 years ago, but a cure has still not been found.
About 50 million people worldwide have dementia, according to the WHO, and Alzheimer s contributes to up to 70% of cases. The WHO estimates that the total number of people with dementia will reach 82 million in 2030 and 152 million in 2050. It s now among the top 10 causes of death, according to the WHO s 2019 Global Health Estimates.
Before the study, the scientists established that in the brains of Alzheimer s patients, key elements of the machinery that allows protein production were depleted in the hippocampus. This led them to think that protein synthesis may also be impaired.
An international research team has described a potential new approach to holding back the loss of cognitive function that occurs with Alzheimer’s disease (AD), which uses a synthetic compound to boost protein synthesis in neurons. The scientists’ studies in mouse models of the neurodegenerative disorder demonstrated how the experimental small molecule could rescue the activity of brain cells needed for memory formation. “This work is the first to show that reversing impaired protein synthesis in brains afflicted by Alzheimer’s disease through a pharmacological approach is not only feasible, but also effective,” commented Mauricio Martins-Oliveira, PhD, a postdoctoral researcher at New York University’s Center for Neural Science, and first author of the team’s paper in
The findings reveal that synthetic pharmaceuticals could rescue the activity of brain cells needed for memory formation.
“This work is the first to show that reversing impaired protein synthesis in brains afflicted by Alzheimer’s disease through a pharmacological approach is not only feasible, but also effective,” says Mauricio Martins-Oliveira, a postdoctoral researcher at New York University’s Center for Neural Science and lead author of the paper in
Currently, treatments for Alzheimer’s disease center on the reduction of phenomena linked to the affliction, such as amyloid plaque load, neurofibrillary tangles, and neuroinflammation. The new study suggests that the addition of a pharmaceutical normalizing protein synthesis could aid in reviving normal brain activity.